By Nick Robertson ( July 7, 2026, 18:01 GMT | Comment) -- The approval of the first generic semaglutide for weight loss in Canada last week highlights key differences in patent regulation between Canada and the US, where the market-leading GLP-1 medication will enjoy patent protection until 2038. Health Canada approved the first generic semaglutide GLP-1 medication for weight loss last week, making Canada the first G7 nation to have a generic GLP-1 receive regulatory approval for its most common use. The relatively quick pace of generic entry, just five years after branded approval, shows a split from the US market, where generic competition isn’t likely for a decade....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.